Highlights from ACC 2026
Bempedoic Acid Protects Statin-Intolerant Individuals Against Ischemic Events
Bempedoic acid provides effective protection against ischemic stroke for patients who cannot tolerate statins, according to a recent analysis from the CLEAR Outcomes trial, a study enrolling nearly 14,000 statin-intolerant patients with significant cardiovascular risk.
March 30, 2026
Read moreRelated Articles
Bempedoic Acid Improved Cardiovascular Outcomes in People with Chronic Inflammation
Individuals with autoimmune and inflammatory diseases can benefit from the cardioprotective effects of bempedoic acid, according to a secondary analysis from the CLEAR Outcomes trial. The analysis presented at the 75th Annual Scientific Session of the American College of Cardiology, in New Orleans, provided a close look at inflammation, cholesterol levels, and cardiovascular outcomes in relation to the absence or presence of underlying inflammation associated with certain chronic diseases.
March 30, 2026
Read moreSecondary Prevention after Coronary Revascularization Remains Inadequate
A retrospective study of more than 22,000 people who underwent coronary revascularization at 25 medical centers in Wisconsin and Illinois showed that many individuals at risk for additional cardiovascular events fail to achieve guideline-recommended lipid-lowering goals. Anya Koza, DO, an internal medicine resident at the Aurora Sinai Medical Center in Milwaukee, Wisconsin, presented the results in a poster session at the 75th Annual Scientific Session of the American College of Cardiology, in New Orleans.
March 30, 2026
Read morePatients at High Risk for Cardiovascular Events Benefit from Intensive Cholesterol-Lowering Targets
An open-label trial enrolling South Korean patients with elevated cardiovascular risk showed that using low-density lipoprotein cholesterol (LDL-C) targets below 55 mg/dL significantly reduced the risk for major adverse cardiovascular events (MACE) over 3 years compared with the use of less stringent goals. Byeong-Keuk Kim, MD, Professor in the Division of Cardiology at Yonsei University, in Seoul, South Korea, presented data on cardiovascular outcomes from the Ez-PAVE trial at the 75th Annual Scientific Session of the American College of Cardiology, in New Orleans.
March 31, 2026
Read moreOvercoming Clinical Inertia in the Management of Patients with Myocardial Infarction
A retrospective analysis presented at the 75th Annual Scientific Session of the American College of Cardiology, in New Orleans, suggested that patients who have experienced a myocardial infarction could benefit from closer monitoring and more intensive lipid-lowering strategies.
March 31, 2026
Read moreBempedoic Acid Proved More Effective Against Stroke and Revascularization than Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors
Individuals with atherosclerotic cardiovascular disease (ASCVD) without diabetes who used bempedoic acid had a lower risk of coronary revascularization and stroke over a 1-year period compared with those treated with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, according to real-world findings presented at ACC 2026 in New Orleans.
March 31, 2026
Read moreDecline in the Proportion of Cardiovascular Deaths Attributed to Myocardial Infarction May Shape Future Lipid-Lowering Strategies
Understanding the shifting balance between nonfatal myocardial infarction (MI) and cardiovascular death (CVD) may help clinicians gauge the impact of lipid-lowering therapies and optimize their clinical strategies, ultimately improving outcomes for patients at high risk for atherosclerotic cardiovascular disease. A study presented at the 75th Annual Scientific Session of the American College of Cardiology, in New Orleans, showed that changes in the MI-to-CVD ratio provides a novel lens for assessing therapy impact and may inform design strategies for future clinical trials.
March 31, 2026
Read moreOnline Risk Calculator Based on Remnant Cholesterol and Inflammatory Markers Can Predict Cardiovascular Mortality
Integrating an online risk calculator based on remnant cholesterol and inflammatory markers into the clinical workflow may help providers identify people at high risk for cardiovascular death and improve outcomes for their patients, according to a population-based study presented at the 75th Annual Scientific Session of the American College of Cardiology, in New Orleans.
March 31, 2026
Read moreRegistry Data Reveal Gaps in the Primary Prevention of Myocardial Infarction
Patients presenting to the hospital with a first acute myocardial infarction often have poorly controlled low-density lipoprotein cholesterol (LDL-C) levels due to the underutilization of lipid-lowering therapies, according to data from the Chest Pain-MI Registry presented at the 75th Annual Scientific Session of the American College of Cardiology, in New Orleans.
April 1, 2026
Read moreTakeaways from the Updated Cholesterol Guidelines: What Should Providers Know?
With the release of the 2026 American College of Cardiology/American Heart Association Multisociety Guideline on the Management of Dyslipidemia, patients and providers are entering a new era of early interventions and more intensive lipid-lowering strategies. The updated recommendations, which replace the 2018 guidelines, emphasize a return to simplified goals while providing clinicians with a myriad of options for managing individuals with diverse needs and different levels of cardiovascular risk. At the 75th Annual Scientific Session of the American College of Cardiology, in New Orleans, experts in preventive cardiology discussed strategies for translating these recommendations into successful treatment strategies.
April 1, 2026
Read morePatients with Cardiovascular Disease and Diabetes Benefit from Intensive Lipid-Lowering Strategies
Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels may significantly decrease risk for cardiovascular events for individuals with atherosclerotic cardiovascular disease (ASCVD) and diabetes, according to real-world data presented at the 75th Annual Scientific Session of the American College of Cardiology, in New Orleans.
April 1, 2026
Read moreRepeat C-Reactive Protein Measurements May Refine Cardiovascular Risk Stratification
An analysis featured at the 75th Annual Scientific Session of the American College of Cardiology, in New Orleans, revealed an association between persistently elevated C-reactive protein (CRP) levels and incident first-time myocardial infarction, highlighting the importance of repeating measurements of inflammatory markers for cardiovascular risk stratification.
March 30, 2026
Read more
© 2026 Wolters Kluwer. All right reserved.